Editorial: HPV Natural History, Immunological Responses and Vaccination Strategies: Challenges and Opportunities

Zheng Quan Toh,Fanghui Zhao,Lei Zhang,Lanlan Wei,Huachun Zou

DOI: https://doi.org/10.3389/fimmu.2023.1349664

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 08 January 2024Sec. Viral Immunology Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1349664

What problem does this paper attempt to address?

Current status and future directions for the development of human papillomavirus vaccines

Rui Wang,Hongpeng Huang,Chulin Yu,Xuefeng Li,Yang Wang,Liangzhi Xie

DOI: https://doi.org/10.3389/fimmu.2024.1362770

IF: 7.3

2024-06-25

Frontiers in Immunology

Abstract:The development of human papillomavirus (HPV) vaccines has made substantive progress, as represented by the approval of five prophylactic vaccines since 2006. Generally, the deployment of prophylactic HPV vaccines is effective in preventing newly acquired infections and incidences of HPV-related malignancies. However, there is still a long way to go regarding the prevention of all HPV infections and the eradication of established HPV infections, as well as the subsequent progression to cancer. Optimizing prophylactic HPV vaccines by incorporating L1 proteins from more HPV subtypes, exploring adjuvants that reinforce cellular immune responses to eradicate HPV-infected cells, and developing therapeutic HPV vaccines used either alone or in combination with other cancer therapeutic modalities might bring about a new era getting closer to the vision to get rid of HPV infection and related diseases. Herein, we summarize strategies for the development of HPV vaccines, both prophylactic and therapeutic, with an emphasis on the selection of antigens and adjuvants, as well as implications for vaccine efficacy based on preclinical studies and clinical trials. Additionally, we outline current cutting-edge insights on formulation strategies, dosing schedules, and age expansion among HPV vaccine recipients, which might play important roles in addressing barriers to vaccine uptake, such as vaccine hesitancy and vaccine availability.

immunology
Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives

Yicheng Mo,Jiabing Ma,Hongtao Zhang,Junjie Shen,Jun Chen,Juan Hong,Yanmin Xu,Cheng Qian

DOI: https://doi.org/10.3389/fcimb.2022.909223

IF: 6.073

2022-07-05

Frontiers in Cellular and Infection Microbiology

Abstract:Persistent human papillomavirus (HPV) infection is recognized as the main cause of cervical cancer and other malignant cancers. Although early detection and treatment can be achieved by effective HPV screening methods and surgical procedures, the disease load has not been adequately mitigated yet, especially in the underdeveloped areas. Vaccine, being regarded as a more effective solution, is expected to prevent virus infection and the consequent diseases in the phases of both prevention and treatment. Currently, there are three licensed prophylactic vaccines for L1-VLPs, namely bivalent, quadrivalent and nonavalent vaccine. About 90% of HPV infections have been effectively prevented with the implementation of vaccines worldwide. However, no significant therapeutic effect has been observed on the already existed infections and lesions. Therapeutic vaccine designed for oncoprotein E6/E7 activates cellular immunity rather than focuses on neutralizing antibodies, which is considered as an ideal immune method to eliminate infection. In this review, we elaborate on the classification, mechanism, and clinical effects of HPV vaccines for disease prevention and treatment, in order to make improvements to the current situation of HPV vaccines by provoking new ideas.

immunology,microbiology
Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China

Lihui Wei,Xing Xie,Jihong Liu,Youlin Qiao,Fanghui Zhao,Ting Wu,Jun Zhang,Ding Ma,Beihua Kong,Wen Chen,Chao Zhao,Yun Zhao,Jingran Li,Mingzhu Li,Ningshao Xia

DOI: https://doi.org/10.1007/s40944-021-00536-6

2021-06-01

Indian Journal of Gynecologic Oncology

Abstract:ObjectiveCervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part.MethodsThere are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the "Chinese Expert Consensus on the Clinical Application of HPV Vaccine."ResultsAt 7 months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9–14 years was 2–3 times higher than that in adult women. Efficacy of the four vaccines against CIN2 + ranged from 87.3% to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12 months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18–45 years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The "Chinese Expert Consensus on the Clinical Application of HPV Vaccine" will work to promote the application of HPV vaccine in China.ConclusionsIn clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.
Opportunities and challenges for human papillomavirus vaccination in China

Chao ZhaoYun ZhaoJingran LiMingzhu LiYujing ShiLihui Weia Gynaecology,Peking University People's Hospital,Beijing,Chinab MRL Global Medical Affairs,MSD China,Shanghai,Chinac Department of Gynecology and Obstetrics,Peking University People's Hospital

DOI: https://doi.org/10.1080/21645515.2024.2329450

2024-04-06

Human Vaccines & Immunotherapeutics

Abstract:Current estimates of the HPV infection rate in China vary by geographic region (9.6–23.6%), with two age peaks in prevalence in women ≤20–25 years of age and 50–60 years of age. HPV-16, 52 and 58 are the most commonly-detected HPV genotypes in the Chinese population. In China, five HPV vaccines are licensed and several others are undergoing clinical trials. Multiple RCTs have shown the efficacy and safety of the bvHPV (Cervarix), Escherichia coli -produced bvHPV (Cecolin), Pichia pastoris -produced bvHPV (Walrinvax), qvHPV (Gardasil) and 9vHPV (Gardasil-9) vaccines in Chinese populations, including two studies showing long-term efficacy (≥8 years) for the bvHPV and qvHPV vaccines. Real-world data from China are scarce. Although modeling studies in China show HPV vaccination is cost-effective, uptake and population coverage are relatively low. Various policies have been implemented to raise awareness and increase vaccine coverage, with the long-term aim of eliminating cervical cancer in China.

immunology,biotechnology & applied microbiology
Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management

Meng Wu,Hui Huang,Ying Tang,Xuze Ren,Xinrui Jiang,Man Tian,Wei Li

DOI: https://doi.org/10.3389/fimmu.2024.1430544

2024-08-08

Abstract:Human Papillomavirus (HPV), an extensive family of DNA viruses, manifests as a persistent global health challenge. Persistent HPV infection is now firmly established as a significant aetiological factor for a spectrum of malignancies. In this review, we examine the latest insights into HPV biology and its intricate relationship with the host. We delve into the complex dynamics of co-infections involving HPV alongside other viruses, such as HIV, EBV, and HSV, as well as the burgeoning role of the microbiome in cancer development. We also explore recent advancements in understanding the specific contributions of HPV in the development of various cancers, encompassing cancers of the anogenital region, head and neck, as well as breast, lung, and prostate. Moreover, we focus on the current preventive strategies, including vaccination and screening methods, and therapeutic interventions that range from traditional approaches like surgery and chemotherapy to emerging modalities such as targeted therapies and immunotherapies. Additionally, we provide a forward-looking view on the future directions of HPV research, highlighting potential areas of exploration to further our understanding and management of HPV and its associated cancers. Collectively, this review is positioned to deepen readers' understanding of HPV biology and its complex interplay with cancer biology. It presents innovative strategies for the prevention, management, and therapeutic intervention of HPV-associated malignancies.
Barriers to and Facilitators of Human Papillomavirus Vaccination among People Aged 9 to 26 Years: A Systematic Review

Luyan Zheng,Jie Wu,Min Zheng

DOI: https://doi.org/10.1097/olq.0000000000001407

2021-01-01

Sexually Transmitted Diseases

Abstract:BACKGROUND:Cervical and oropharyngeal cancers are associated with human papillomavirus (HPV) infection, which can be prevented with the vaccines. However, uptake of the HPV vaccine remains low in many countries. There is a need to better understand the barriers to and facilitators of HPV vaccination from young people's perspectives. METHODS:Five electronic databases were searched for original publications (dated January, 2006-December, 2019) reporting barriers to and facilitators of HPV vaccination among young people. All articles were screened against prespecified eligibility criteria, and data were extracted against prespecified form. RESULTS:A total of 13 studies that were published in international peer-reviewed journals and met the stated eligibility criteria were identified. The barriers reported were centralized around lack of knowledge about HPV and the HPV vaccine, fear about the safety and efficacy of the HPV vaccine, fear about not being able to pay for the HPV vaccine, and discrimination regarding to the HPV vaccine. The facilitators reported were centralized around trust in the efficacy and safety of the HPV vaccine, discounted price of vaccination, positive recommendations from others, perceived risk of HPV infection, and benefits of vaccine. CONCLUSIONS:After their introduction 14 years ago, knowledge deficiency of the HPV vaccine is still a critical barrier to vaccination. Educational initiatives aimed at adolescents and young adults were urgently needed. Understanding factors that arbitrate in early HPV vaccination is critical for improving the HPV vaccination rate.
Clinical application progress and thoughts about HPV prophylactic vaccines

Lin Cheng,Kun Zhang,Tianmin Xu

DOI: https://doi.org/10.3969/j.issn.1672-4992.2017.02.45

2017-01-01

Abstract:Cervical cancer is the most common cancer in female genitourinary system.The close relationship between high -risk human papillomavirus(HPV)persistent infection and cervical cancer had been confirmed by epidemiology studies.Hence,HPV vaccine has attracted tremendous attention on preventing HPV infection and cervical lesions. Our review focusd on the three types of HPV prophylactic vaccines which have been approved for marketing by FDA. We also list some controversies which could draw more attention and thought -provoking.
Perspectives for therapeutic HPV vaccine development

Andrew Yang,Emily Farmer,T. C. Wu,Chien-Fu Hung

DOI: https://doi.org/10.1186/s12929-016-0293-9

2016-11-04

Journal of Biomedical Science

Abstract:BackgroundHuman papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide. It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects against established HPV infections and lesions. These concerns create a critical need for the development of therapeutic strategies, such as vaccines, to treat these existing infections and diseases.Main BodyUnlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV vaccine clinical trials.ConclusionGreat progress has been made to develop and improve novel therapeutic HPV vaccines to treat existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated diseases in the near future.

cell biology,medicine, research & experimental
Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies

Ying Liu,Hao Ai

DOI: https://doi.org/10.1016/j.bbcan.2024.189192

2024-09-29

Abstract:This article provides an in-depth review of the Human Papillomavirus (HPV), a predominant etiological factor in cervical cancer, exploring its pathophysiology, epidemiology, and mechanisms of oncogenesis. We examine the role of proteins, DNA methylation markers, and non-coding RNAs as predictive biomarkers in cervical cancer, highlighting their potential in refining diagnostic and prognostic practices. The evolution and efficacy of cervical cancer screening methods, including the Papanicolaou smear, HPV testing, cytology and HPV test, and colposcopy techniques, are critically analyzed. Furthermore, the article delves into the current landscape and future prospects of prophylactic HPV vaccines and therapeutic vaccines, underscoring their significance in the prevention and potential treatment of HPV-related diseases. This comprehensive review aims to synthesize recent advances and ongoing challenges in the field, providing a foundation for future research and clinical strategies in the prevention and management of cervical cancer.
Trend of HPV Molecular Epidemiology in the Post-Vaccine Era: A 10-Year Study

Yueh Lin,Wan-Ying Lin,Ting-Wei Lin,Yi-Ju Tseng,Yu-Chiang Wang,Jia-Ruei Yu,Chia-Ru Chung,Hsin-Yao Wang

DOI: https://doi.org/10.3390/v15102015

2023-09-27

Viruses

Abstract:Cervical cancer, a major health concern among women worldwide, is closely linked to human papillomavirus (HPV) infection. This study explores the evolving landscape of HPV molecular epidemiology in Taiwan over a decade (2010-2020), where prophylactic HPV vaccination has been implemented since 2007. Analyzing data from 40,561 vaginal swab samples, with 42.0% testing positive for HPV, we reveal shifting trends in HPV genotype distribution and infection patterns. The 12 high-risk genotypes, in order of decreasing percentage, were HPV 52, 58, 16, 18, 51, 56, 39, 59, 33, 31, 45, and 35. The predominant genotypes were HPV 52, 58, and 16, accounting for over 70% of cases annually. The proportions of high-risk and non-high-risk HPV infections varied across age groups. High-risk infections predominated in sexually active individuals aged 30-50 and were mixed-type infections. The composition of high-risk HPV genotypes was generally stable over time; however, HPV31, 33, 39, and 51 significantly decreased over the decade. Of the strains, HPV31 and 33 are shielded by the nonavalent HPV vaccine. However, no reduction was noted for the other seven genotypes. This study offers valuable insights into the post-vaccine HPV epidemiology. Future investigations should delve into HPV vaccines' effects and their implications for cervical cancer prevention strategies. These findings underscore the need for continued surveillance and research to guide effective public health interventions targeting HPV-associated diseases.
Editorial: Molecular Landscapes of Human Papillomavirus-Related Squamous Cell Carcinoma

Yujie Shen,Jinhui Liu

DOI: https://doi.org/10.3389/fonc.2023.1215142

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:COPYRIGHT © 2023 Shen and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Editorial PUBLISHED 31 May 2023 DOI 10.3389/fonc.2023.1215142
Human Papillomavirus Vaccines: An Updated Review

Liqin Cheng,Yan Wang,Juan Du

DOI: https://doi.org/10.3390/vaccines8030391

2020-07-16

Vaccines

Abstract:Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated information about current HPV vaccines, focusing on vaccine coverage and efficacy. In addition, pan-gender vaccination and current clinical trials are also discussed. Currently, more efforts should be put into increasing the vaccine’s coverage, especially in low- and middle-income countries. Provision of education on HPV and vaccination is one of the most important methods to achieve this. Vaccines that target HPV types not included in current vaccines are the next stage in vaccine development. In the future, all HPV-related cancers, such as head and neck cancer, and anal cancer, should be tracked and evaluated, especially in countries that have introduced pan-gender vaccination programs. Therapeutic vaccines, in combination with other cancer treatments, should continue to be investigated.

immunology,medicine, research & experimental
Therapeutic DNA Vaccines Against HPV-Related Malignancies: Promising Leads from Clinical Trials

Jianming Tang,Mingzhu Li,Chao Zhao,Danhua Shen,Lei Liu,Xiujun Zhang,Lihui Wei

DOI: https://doi.org/10.3390/v14020239

2022-01-01

Viruses

Abstract:In 2014 and 2021, two nucleic-acid vaccine candidates named MAV E2 and VGX-3100 completed phase III clinical trials in Mexico and U.S., respectively, for patients with human papillomavirus (HPV)-related, high-grade squamous intraepithelial lesions (HSIL). These well-tolerated but still unlicensed vaccines encode distinct HPV antigens (E2 versus E6+E7) to elicit cell-mediated immune responses; their clinical efficacy, as measured by HSIL regression or cure, was modest when compared with placebo or surgery (conization), but both proved highly effective in clearing HPV infection, which should help further optimize strategies for enhancing vaccine immunogenicity, toward an ultimate goal of preventing malignancies in millions of patients who are living with persistent, oncogenic HPV infection but are not expected to benefit from current, prophylactic vaccines. The major roadblocks to a highly efficacious and practical product remain challenging and can be classified into five categories: (i) getting the vaccines into the right cells for efficient expression and presentation of HPV antigens (fusion proteins or epitopes); (ii) having adequate coverage of oncogenic HPV types, beyond the current focus on HPV-16 and -18; (iii) directing immune protection to various epithelial niches, especially anogenital mucosa and upper aerodigestive tract where HPV-transformed cells wreak havoc; (iv) establishing the time window and vaccination regimen, including dosage, interval and even combination therapy, for achieving maximum efficacy; and (v) validating therapeutic efficacy in patients with poor prognosis because of advanced, recurrent or non-resectable malignancies. Overall, the room for improvements is still large enough that continuing efforts for research and development will very likely extend into the next decade.
HPV Vaccine: Updates and Highlights

Cristina Mendes de Oliveira,José Humberto T.G. Fregnani,Luisa Lina Villa,Cristina Mendes de Oliveira,José Humberto T.G. Fregnani,Luisa Lina Villa

DOI: https://doi.org/10.1159/000497617

2019-01-01

Acta Cytologica

Abstract:HPV is the most common sexually transmitted biological agent and is the cause of many conditions in men and women, including precancer lesions and cancer. Three prophylactic HPV vaccines targeting high-risk HPV types are available in many countries worldwide: 2-, 4- and 9-valent vaccines. All the 3 vaccines use recombinant DNA technology and are prepared from the purified L1 protein that self-assembles to form HPV type-specific empty shells. This non-systematic review aims to summarize the HPV epidemiology and the vaccine development to review the landmark trials of HPV vaccine, to present to most remarkable results from clinical trials and the real world, and to stress the challenges and the barriers for HPV vaccine implementation.

pathology
Current Strategies Against Persistent Human Papillomavirus Infection (Review)

Yu Liu,Hongyi Li,Ruyu Pi,Yang Yang,Xia Zhao,Xiaorong Qi

DOI: https://doi.org/10.3892/ijo.2019.4847

2019-01-01

International Journal of Oncology

Abstract:Human papillomavirus (HPV) is the most common sexually transmitted infection, exhibiting a tropism for the epidermis and mucosae. The link between persistent HPV infection and malignancies involving the anogenital tract as well as the head and neck has been well-established, and it is estimated that HPV-related cancers involving various anatomical sites account for 4.5% of all human cancers. Current prophylactic vaccines against HPV have enabled the prevention of associated malignancies. However, the sizeable population base of current infection in whom prophylactic vaccines are not applicable, certain high-risk HPV types not included in vaccines, and the vast susceptible population in developing countries who do not have access to the costly prophylactic vaccines, put forward an imperative need for effective therapies targeting persistent infection. In this article, the life cycle of HPV, the mechanisms facilitating HPV evasion of recognition and clearance by the host immune system, and the promising therapeutic strategies currently under investigation, particularly antiviral drugs and therapeutic vaccines, are reviewed.
Developmental History of HPV Prophylactic Vaccines

John T. Schiller,Douglas R. Lowy

DOI: https://doi.org/10.1007/978-1-4419-1339-5_27

2011-01-01

Abstract:Prophylactic human papillomavirus (HPV) vaccines are a recent addition to our vaccine arsenal, first becoming commercially available in mid-2006. Although they have not yet made a public health impact, they likely represent an important addition to cancer prevention strategies. Their development is the result of a fortunate temporal convergence of two distinct lines of scientific enquiry. One produced the molecular biological and epidemiological evidence that established, beyond a reasonable doubt, that HPV infection is the central cause of cervical cancer. The second was the development of molecular technologies for production of the L1 virus-like particles (VLPs) vaccines and serological assays to measure their immunogenicity. HPV vaccine development and clinical testing was based on both critical lessons learned in the development of other vaccines and solutions to unique problems that arose because of the specific biology of HPVs and their relationship to neoplastic disease. This review offers our reflection on some of the milestones in the preclinical and clinical development of HPV prophylactic vaccine and includes some of our personal experiences in the enterprise. It is not meant to be a comprehensive review of the subject.
Prevalence and Distribution of Human Papillomavirus Genotypes in Chinese Women Between 1991 and 2016: A Systematic Review

Hong-Lu Zhou,Wei Zhang,Can-Jing Zhang,Song-Mei Wang,Ya-Chen Duan,Jin-Xia Wang,Huan Yang,Xuan-Yi Wang

DOI: https://doi.org/10.1016/j.jinf.2018.02.008

IF: 28.2

2018-01-01

Journal of Infection

Abstract:Background: Human papillomavirus (HPV) associated cervical cancer is one of the most common cancers and ranked as the eighth most common killer for Chinese women. A dozen of HPV vaccines are being developed in China without a solid China-specific distribution of carcinogenic HPV types, thus, we performed this systematic review to explore the China-specific spectrum of high-risk types causing cancer. Methods: Studies on HPV infection among Chinese women were searched. All retrieved articles were screened and reviewed by a standardized algorithm. Distribution of carcinogenic HPV types and age-specific prevalence were analyzed using random-effects model. Results: A total of 303 articles were included in the final analysis. The top 10 common HPV types detected in ICC patients, in descending order of frequency, were HPV 16 (62.5%), 18 (12.4%), 58 (8.6%), 52 (5.7%), 33 (4.6%), 31 (3.5%), 55 (2.4%), 68 (2.4%), 53 (2.2%) and 45 (2.0%) respectively. Similar spectrum was found in women with precancer. The prevalence of HPV infection peaked between 20 and 24 years with a rate of 24.3%, thereafter declined substantially and stabilized at middle-ages. Compared to women living in the developed provinces, the second peak was observed among women aged 45-55 years in less developed regions. Conclusion: In general, the spectrum of HPV types in women with precancer/cancer and the pattern of age-specific prevalence were consistent with that of elsewhere worldwide. However, some distinguished characteristics could also be concluded, and these imprinting should be considered and integrated when developing vaccines and strategy for disease control in China. (C) 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Current and future direction in treatment of HPV-related cervical disease

Bolhassani, Azam

DOI: https://doi.org/10.1007/s00109-022-02199-y

2022-04-29

Journal of Molecular Medicine

Abstract:Human papillomavirus (HPV) is the most common sexually transmitted virus in the world. About 70% of cervical cancers are caused by the most oncogenic HPV genotypes of 16 and 18. Since available prophylactic vaccines do not induce immunity in those with established HPV infections, the development of therapeutic HPV vaccines using E6 and E7 oncogenes, or both as the target antigens remains essential. Also, knocking out the E6 and E7 oncogenes in host genome by genome-editing CRISPR/Cas system can result in tumor growth suppression. These methods have shown promising results in both preclinical and clinical trials and can be used for controlling the progression of HPV-related cervical diseases. This comprehensive review will detail the current treatment of HPV-related cervical precancerous and cancerous diseases. We also reviewed the future direction of treatment including different kinds of therapeutic methods and vaccines, genome-editing CRISPR/Cas system being studied in clinical trials. Although the progress in the development of therapeutic HPV vaccine has been slow, encouraging results from recent trials showed vaccine-induced regression in high-grade CIN lesions. CRISPR/Cas genome-editing system is also a promising strategy for HPV cancer therapy. However, its safety and specificity need to be optimized before it is used in clinical setting.
Previous History and Cigarette Smoking As Interfering Factors for the Effect of Vaccine on Human Papillomavirus Infection

Haifeng Pei,Yu Q,Qinghong Xue,Wei Fan,Tao Lei

DOI: https://doi.org/10.1093/infdis/jit837

2013-01-01

Abstract:virus (HPV)-associated cancers and HPV vaccination coverage levels and RE: inequalities in human papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination. J Natl Cancer Inst 2013; 105:749–50. 7. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13–17 years— United States. 2011. MMWR 2012; 34:671–7. 8. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813–9. 9. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793–802. 10. Harper DM, Vierthaler SL, Santee JA. Review of gardasil. J Vaccines Vaccin 2010; 1. doi:pii: 1000107. 11. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl 5): F12–23.
Advances in Etiopathological Role and Control of HPV in Cervical Cancer Oncogenesis

Kombe,Samira Zoa‐Assoumou,Guy‐Armel Bounda,Fleury-Augustin Nsole-Biteghe,Tengchuan Jin,Abdou Azaque Zouré

DOI: https://doi.org/10.31083/j.fbl2810245

2023-01-01

Frontiers in Bioscience

Abstract:The human papillomavirus (HPV) is a well-known oncovirus whose causal link in the occurrence and development of several cancers, such as cervical cancer (CC), has been well established. Indeed, numerous researches depicted the etiological role of HPV in CC pathogenesis in such a way as to develop efficient strategies, including early diagnoses and HPV vaccination, to mitigate HPV infection and CC occurrence. Despite the effectiveness of these strategies in preventing HPV infection, its persistence, and the progression to precancerous lesions and cancers, extensive work that could give a better understanding of other unknown factors favoring oncogenesis is much more needed. In this last decade, scarce or few but crucial and strategic studies have been carried out to improve and deepen our understanding of the etiopathological role of HPV in the progression towards the development of CC. In this review, we highlighted the recent findings on the pathological role of HPV in CC occurrence and the advances in novel adopted strategies to reduce HPV infection and prevent CC occurrence more effectively.

Editorial: HPV Natural History, Immunological Responses and Vaccination Strategies: Challenges and Opportunities

Current status and future directions for the development of human papillomavirus vaccines

Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives

Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China

Opportunities and challenges for human papillomavirus vaccination in China

Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management

Barriers to and Facilitators of Human Papillomavirus Vaccination among People Aged 9 to 26 Years: A Systematic Review

Clinical application progress and thoughts about HPV prophylactic vaccines

Perspectives for therapeutic HPV vaccine development

Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies

Trend of HPV Molecular Epidemiology in the Post-Vaccine Era: A 10-Year Study

Editorial: Molecular Landscapes of Human Papillomavirus-Related Squamous Cell Carcinoma

Human Papillomavirus Vaccines: An Updated Review

Therapeutic DNA Vaccines Against HPV-Related Malignancies: Promising Leads from Clinical Trials

HPV Vaccine: Updates and Highlights

Current Strategies Against Persistent Human Papillomavirus Infection (Review)

Developmental History of HPV Prophylactic Vaccines

Prevalence and Distribution of Human Papillomavirus Genotypes in Chinese Women Between 1991 and 2016: A Systematic Review

Current and future direction in treatment of HPV-related cervical disease

Previous History and Cigarette Smoking As Interfering Factors for the Effect of Vaccine on Human Papillomavirus Infection

Advances in Etiopathological Role and Control of HPV in Cervical Cancer Oncogenesis